{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:46Z","timestamp":1788265006639,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neo.2026.101343","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T18:48:39Z","timestamp":1785696519000},"page":"101343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prophylactic folinic acid prevents pemetrexed myelosuppression: A randomized trial toward safer treatment with chemotherapy in non-small cell lung cancer"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7580-8698","authenticated-orcid":false,"given":"Ramon","family":"Contrucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3439","authenticated-orcid":false,"given":"Merel","family":"Tonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9437-0533","authenticated-orcid":false,"given":"Jeroen","family":"Diepstraten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"van Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"van Kesteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel van den","family":"Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-0552","authenticated-orcid":false,"given":"Nikki","family":"de Rouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neo.2026.101343_bib0001","first-page":"545","article-title":"Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy","volume":"1","author":"Niyikiza","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.neo.2026.101343_bib0002","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101343_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.neo.2026.101343_bib0004","unstructured":"Janne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 2025."},{"issue":"21","key":"10.1016\/j.neo.2026.101343_bib0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.neo.2026.101343_bib0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.neo.2026.101343_bib0007","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","article-title":"Management and prevention of pemetrexed-related toxicity","volume":"44","author":"de Rouw","year":"2021","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.neo.2026.101343_bib0008","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from Pemetrexed and Pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2026.101343_bib0009","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2021.02.021","article-title":"Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189","volume":"155","author":"Garon","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2026.101343_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","article-title":"Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study","volume":"121","author":"Visser","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2026.101343_bib0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","article-title":"Cumulative pemetrexed dose increases the risk of nephrotoxicity","volume":"146","author":"de Rouw","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2026.101343_bib0012","unstructured":"National Institutes of Health NCI. Common terminology criteria for adverse events (CTCAE). In: Services USDoHaH, editor.; 2010."},{"issue":"14","key":"10.1016\/j.neo.2026.101343_bib0013","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.neo.2026.101343_bib0014","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.neo.2026.101343_bib0015","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2008.19.4522","article-title":"Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials","volume":"27","author":"Soon","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2026.101343_bib0016","first-page":"1576","article-title":"Toxicity of pemetrexed during renal impairment explained \u2013 implications for safe treatment","volume":"149","author":"Boosman","year":"2021","journal-title":"Int. J. Cancer 2021 Oct 15"},{"issue":"22","key":"10.1016\/j.neo.2026.101343_bib0017","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.neo.2026.101343_bib0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/cpt.2529","article-title":"The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer","volume":"111","author":"de Rouw","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5A","key":"10.1016\/j.neo.2026.101343_bib0019","first-page":"3235","article-title":"Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514","volume":"18","author":"Worzalla","year":"1998","journal-title":"Anticancer Res."},{"issue":"23","key":"10.1016\/j.neo.2026.101343_bib0020","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.neo.2026.101343_bib0021","first-page":"3646","article-title":"Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies","volume":"6","author":"Farrugia","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101343_bib0022","doi-asserted-by":"crossref","unstructured":"de Rouw N, Otten LS, Kicken MP, et al. Folinic acid prophylaxis and dose adjustments enable safe treatment with Pemetrexed in patients with renal impairment. Clin. Pharmacol. Ther. 2025.","DOI":"10.1002\/cpt.3735"},{"issue":"5","key":"10.1016\/j.neo.2026.101343_bib0023","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdf115","article-title":"Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer","volume":"13","author":"Clarke","year":"2002","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.neo.2026.101343_bib0024","first-page":"605","article-title":"A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate","volume":"4","author":"McDonald","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101343_bib0025","unstructured":"Pemetrexed summary of product characteristics (SMPC). In: (EMA) EMA, editor. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pemetrexed-medac-epar-product-information_en.pdf; 2020."},{"key":"10.1016\/j.neo.2026.101343_bib0026","unstructured":"Rescuvolin 15mg tablets summary of product characteristics 2019."},{"issue":"10","key":"10.1016\/j.neo.2026.101343_bib0027","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.116.070722","article-title":"Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral Human organic anion transporter 3","volume":"44","author":"Ikemura","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neo.2026.101343_bib0028","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2022.02.007","article-title":"Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: the prospective IPPEM study","volume":"166","author":"Slimano","year":"2022","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.neo.2026.101343_bib0029","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101343_bib0030","first-page":"42","article-title":"Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis","volume":"26","author":"Mendelsohn","year":"1999","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.neo.2026.101343_bib0031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","article-title":"Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma","volume":"8","author":"Lustgarten","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2026.101343_bib0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.neo.2026.101343_bib0033","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.neo.2026.101343_bib0034","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann. Intern. Med."},{"issue":"24","key":"10.1016\/j.neo.2026.101343_bib0035","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.neo.2026.101343_bib0036","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00280-005-0077-5","article-title":"A semimechanistic-physiologic population pharmacokinetic\/pharmacodynamic model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"issue":"7","key":"10.1016\/j.neo.2026.101343_bib0037","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-121-7-199410010-00004","article-title":"Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial","volume":"121","author":"Maher","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neo.2026.101343_bib0038","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-13-386","article-title":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy","volume":"13","author":"Bondarenko","year":"2013","journal-title":"BMC. Cancer"},{"issue":"7","key":"10.1016\/j.neo.2026.101343_bib0039","first-page":"716","article-title":"Targeting anemia in patients with lung cancer","volume":"1","author":"Crawford","year":"2006","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2026.101343_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171066","article-title":"Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: a retrospective cohort study","volume":"12","author":"Kawazoe","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.neo.2026.101343_bib0041","unstructured":"Guideline for the use of granulocyte colony stimulating factors (G-CSF) in adult haemato-oncology patients NHS cancer network, 2012."},{"issue":"1","key":"10.1016\/j.neo.2026.101343_bib0042","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:38:39Z","timestamp":1788262719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S1476558626000746"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101343","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic folinic acid prevents pemetrexed myelosuppression: A randomized trial toward safer treatment with chemotherapy in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101343"}}